ALDX - NASDAQ

Aldeyra Therapeutics, Inc.

ALDX·NASDAQ

$1.78

-3.6%

HealthcareBiotechnology

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$107.37M

EPS-0.5600

P/E Ratio-3.18

Earnings Date07/31/2026

72.06M

Assets

-31%

3Y-60.0%

5Y-14.0%

10Y+186.0%

27.81M

Total Liabilities

-17%

3Y-8.0%

5Y+17.0%

10Y+686.0%

44.25M

Total Equity

-38%

3Y-71.0%

5Y-26.0%

10Y+104.0%

Aldeyra Therapeutics, Inc. Funding & Solvency Profile

ALDX · NASDAQ

Current Assets

Cash & Cash Equivalents70.04M

Net Receivables0.00

Inventory0.00

Other Current Assets1.34M

Total Current Assets72 M

Non-Current Assets

Property, Plant & Equipment275.86K

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets0.00

Total Non-Current Assets276 K

Total Assets

72.06M

Financial Health Analysis

Current Ratio

2.58x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.63x

Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.

Working Capital

44 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

100% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Aldeyra Therapeutics, Inc. Balance Sheet

ALDX • NASDAQ

Aldeyra Therapeutics, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	70M	54.5M	142.8M	144.4M	229.8M	77.9M	44.4M	47.4M	20M	12M	14.6M	8.5M	3.3M	1.2M	251K
Short-Term Investments	0.0	46.6M	0.0	29.9M	0.0	0.0	28.9M	46.2M	22.9M	12.9M	12.9M	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	70M	101.2M	142.8M	174.3M	229.8M	77.9M	73.4M	93.6M	42.9M	24.9M	27.6M	8.5M	3.3M	1.2M	251K
Net Receivables	0.0	0.0	0.0	3.2M	28.8K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	750.4K	0.0
Accounts Receivables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	750.4K	0.0
Other Receivables	0.0	0.0	0.0	3.2M	28.8K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	407.2K	408.1K	340.4K	432.2K	435.4K	407.2K	401.3K	1.2M	1M	218.7K	497.6K	232.6K	8.4K	3K	4.2K
Other Current Assets	1.3M	2.5M	4.6M	3M	2.5M	4.8M	1.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Current Assets	71.8M	104.1M	147.8M	181M	232.8M	83.1M	75.2M	94.8M	44M	25.1M	28.1M	8.8M	3.3M	2M	255.2K
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	275.9K	267K	516.6K	268.5K	384.4K	293.2K	349.5K	235.2K	43.3K	56.4K	80.3K	13K	0.0	0.0	3.7K
Other Non-Current Assets	0.0	267.3K	0.0	0.0	0.0	0.0	0.0	86.6K	165.9K	0.0	36.2K	14.2K	472.5K	0.0	0.0
Total Non-Current Assets	275.9K	534.2K	516.6K	268.5K	384.4K	293.2K	349.5K	321.9K	209.2K	56.4K	116.6K	27.2K	472.5K	0.0	3.7K
Total Assets	72.1M	104.6M	148.3M	181.3M	233.1M	83.4M	75.5M	95.1M	44.2M	25.2M	28.2M	8.8M	3.7M	2M	258.9K
LIABILITIES
CURRENT LIABILITIES
Total Payables	158.5K	180.5K	1.3M	133.6K	1M	2.9M	808.3K	3.1M	1M	275.4K	851.2K	341.3K	341.9K	81.4K	25.3K
Accounts Payable	158.5K	180.5K	1.3M	133.6K	1M	381.6K	808.3K	3.1M	1M	275.4K	851.2K	341.3K	341.9K	72.5K	25.3K
Other Payables	0.0	0.0	0.0	0.0	0.0	2.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.8K	0.0
Accrued Expenses	1.8M	7.8M	2.4M	10.2M	9M	4.3M	10.4M	4.2M	1.4M	962.8K	773.3K	463.9K	111.2K	102.5K	293.2K
Short Term Debt	15.2M	31.4K	15.1M	911.8K	0.0	3.7M	0.0	0.0	116.3K	77.5K	77.5K	77.5K	143.2K	166.7K	2.2M
Capital Lease Obligations (Current)	280.5K	271.6K	239.2K	249.3K	229.6K	233.3K	226.3K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Payables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	16.1K	8.8K	0.0
Deferred Revenue	6M	6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	16.1K	8.8K	0.0
Other Current Liabilities	4.3M	4.3M	3.1M	3.8M	1.5M	1.3M	1.5M	1.2M	788.6K	983.4K	413.2K	444.8K	8.8K	12.9K	75K
Total Current Liabilities	27.8M	18.6M	22.3M	15.4M	11.8M	12.4M	12.9M	8.5M	3.4M	2.3M	2.1M	1.3M	605K	363.4K	2.6M
NON-CURRENT LIABILITIES
Long Term Debt	0.0	15M	0.0	14.9M	15.5M	11.4M	14.5M	0.0	1.2M	1.2M	1.2M	1.2M	1.1M	266.3K	0.0
Deferred Revenue (Non-Current)	0.0	0.0	6M	0.0	0.0	0.0	-40.4K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	54.9K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.9M	26.5M	0.0
Total Non-Current Liabilities	0.0	15M	6.3M	14.9M	15.6M	11.4M	14.5M	0.0	1.2M	1.2M	1.2M	1.2M	1.5M	26.8M	0.0
Capital Lease Obligations	280.5K	271.6K	510.8K	249.3K	354.8K	233.3K	226.3K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	27.8M	33.6M	28.5M	30.3M	27.4M	23.8M	27.4M	8.5M	4.6M	3.5M	3.3M	2.5M	2.1M	27.1M	2.6M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	38.3M	29.2M	13.2M
Common Stock	60.2K	59.6K	59.2K	58.6K	58.1K	38.7K	28.7K	26.2K	19.1K	12.6K	9.7K	5.6K	327.0	314.0	3.8K
Additional Paid-In Capital	528.1M	521M	514M	507.8M	500.4M	296.4M	247.4M	225.1M	139.2M	98.9M	83.5M	52.8M	1.1M	0.0	0.0
Retained Earnings	-484M	-450.1M	-394.3M	-356.7M	-294.7M	-236.9M	-199.4M	-138.5M	-99.6M	-77.3M	-58.6M	-46.5M	-41.3M	-54.4M	-15.5M
Accumulated Other Comprehensive Income/Loss	0.0	37.4K	0.0	-103.9K	0.0	0.0	5.9K	-9.2K	-17.8K	129.0	-8.4K	0.0	0.0	0.0	0.0
Total Stockholders' Equity	44.3M	71M	119.8M	151M	205.7M	59.5M	48.1M	86.6M	39.6M	21.6M	24.9M	6.3M	-1.9M	-25.2M	-2.3M
Total Equity	44.3M	71M	119.8M	151M	205.7M	59.5M	48.1M	86.6M	39.6M	21.6M	24.9M	6.3M	1.6M	-25.2M	-2.3M
SUMMARY
Total Liabilities & Equity	72.1M	104.6M	148.3M	181.3M	233.1M	83.4M	75.5M	95.1M	44.2M	25.2M	28.2M	8.8M	3.7M	2M	258.9K
Total Investments	0.0	46.6M	0.0	29.9M	0.0	0.0	28.9M	46.2M	22.9M	12.9M	12.9M	0.0	0.0	0.0	0.0
Total Debt	15.5M	15.3M	15.7M	16.1M	15.9M	15.3M	14.8M	0.0	1.3M	1.3M	1.3M	1.3M	1.3M	432.9K	2.2M
Net Debt	-54.5M	-39.2M	-127.2M	-128.3M	-213.9M	-62.5M	-29.7M	-47.4M	-18.7M	-10.7M	-13.4M	-7.3M	-2M	-790.7K	1.9M
Shares Outstanding	60,045,530	60,045,530	60,045,530	60,045,530	60,045,530	60,045,530	60,045,530	60,045,530	60,045,530	60,045,530	60,045,530	60,045,530	60,045,530	60,045,530	60,045,530

SEC Filings

ALDX - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 07, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 01, 2026	May 01, 2026	2026	View Filing
DEF 14A DEF 14A 2025 N/A	April 27, 2026	June 10, 2025	2025	View Filing
8-K 8-K 2026 N/A	April 20, 2026	April 20, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 01, 2026	April 01, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 17, 2026	March 17, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 27, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2025 N/A	December 31, 2025	December 23, 2025	2025	View Filing
8-K 8-K 2025 N/A	December 16, 2025	December 15, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 13, 2025	November 13, 2025	2025	View Filing

Showing 1 to 10 of 251 filings

Related Guides

Blog Categories

Continue your ALDX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.